scholarly article | Q13442814 |
meta-analysis | Q815382 |
P356 | DOI | 10.1016/S0090-4295(01)01344-9 |
P698 | PubMed publication ID | 11711348 |
P50 | author | Peter Boyle | Q2074086 |
P2093 | author name string | Roehrborn CG | |
Robertson C | |||
Padley RJ | |||
Manski R | |||
P2860 | cites work | The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association | Q33846043 |
Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia | Q33895865 | ||
Medical therapy for benign prostatic hyperplasia: a review of the literature | Q33946113 | ||
A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia | Q38533290 | ||
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia | Q39421840 | ||
Benign prostatic hyperplasia. Current pharmacological treatment | Q39489093 | ||
Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial | Q39498971 | ||
alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia | Q40403192 | ||
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia | Q40488158 | ||
Meta-analysis of published clinical trials of a ribosomal vaccine (ribomunyl) in prevention of respiratory infections | Q44902153 | ||
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group | Q45335490 | ||
Bayesian approaches to random-effects meta-analysis: a comparative study. | Q52320769 | ||
The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. | Q53628573 | ||
Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. | Q54637719 | ||
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials | Q56995126 | ||
Validation of a symptoms questionnaire for benign prostatic hyperplasia | Q67464054 | ||
Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy | Q67465973 | ||
A general parametric approach to the meta-analysis of randomized clinical trials | Q67861093 | ||
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group | Q71678289 | ||
Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial | Q73807682 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 717-722 | |
P577 | publication date | 2001-11-01 | |
P1433 | published in | Urology | Q7900884 |
P1476 | title | Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia | |
P478 | volume | 58 |
Q53288113 | A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. |
Q36852683 | A review of combination therapy in patients with benign prostatic hyperplasia |
Q44696102 | Comprehensive analysis of clinical trials data shows unequivocally that Phosphodiesterase Inhibitors (PDEi) improve orgasm. The power of meta-analysis? |
Q33961645 | Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia |
Q64928433 | Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study. |
Q34643351 | Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia |
Q24795452 | Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials |
Q36542846 | How do I treat and follow my TUNA patients |
Q36511604 | Management of bladder, prostatic and pelvic floor disorders |
Q52407108 | Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination. |
Q33588534 | Medical treatment of benign prostatic hyperplasia |
Q44951587 | Meta-analysis: creating a level playing field for the patient with symptomatic benign prostatic hyperplasia? |
Q34639437 | Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. |
Q47352521 | Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia |
Q39312097 | Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results |
Q39392083 | Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study |
Q24234560 | Terazosin for benign prostatic hyperplasia |
Q30880131 | Terazosin for benign prostatic hyperplasia. |
Q35855002 | The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia |
Q35185800 | The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia |
Q37323301 | The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia |